Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013

Vascular Medicine Department, University Hospital, UJF-Grenoble 1/CNRS TIMC-IMAG UMR 5525/Themas, Grenoble, France. Electronic address: .
Archives of cardiovascular diseases (Impact Factor: 1.66). 06/2013; 32(10). DOI: 10.1016/j.acvd.2013.04.009
Source: PubMed

ABSTRACT New direct oral anticoagulants (NOAC), inhibitors of factor IIa or Xa, are expected to be widely used for the treatment of venous thromboembolic disease, or in case of atrial fibrillation. Such anticoagulant treatments are known to be associated with haemorrhagic complications. Moreover, it is likely that such patients on long-term treatment with NOAC will be exposed to emergency surgery or invasive procedures. Due to the present lack of experience in such conditions, we cannot make recommendations, but only propose management for optimal safety as regards the risk of bleeding in such emergency conditions. In this article, only dabigatran and rivaroxaban were discussed. For emergency surgery at risk of bleeding, we propose to dose the plasmatic concentration of drug. Levels inferior or equal to 30 ng/mL for both dabigatran and rivaroxaban, should enable the realization of a high bleeding risk surgery. For higher concentration, it was proposed to postpone surgery by monitoring the evolution of the drug concentration. Action is then defined by the kind of NOAC and its concentration. If the dosage of the drug is not immediately available, proposals only based on the usual tests, PT and aPTT, also are presented. However, these tests do not really assess drug concentration or bleeding risk. In case of severe haemorrhage in a critical organ, it is proposed to reduce the effect of anticoagulant therapy using a nonspecific procoagulant drug (activated prothrombin concentrate, FEIBA, 30-50 U/kg, or non-activated 4-factors prothrombin concentrates 50 U/kg). For any other type of severe haemorrhage, the administration of such a procoagulant drug, potentially thrombogenic in these patients, will be discussed regarding concentration of NACO and possibilities for mechanical haemostasis.

Download full-text


Available from: Nadia Rosencher, Jul 04, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Rivaroxaban is an oral, selective direct factor Xa inhibitor approved for several indications in patients at risk of thrombotic events. One limitation of its clinical use is the lack of data pertaining to its reversal in situations where urgent response is critical (e.g. acute bleeding events or emergency surgery). Materials and methods: This study assessed the effectiveness of a four-factor prothrombin complex concentrate (4F-PCC; Beriplex (R)/Kcentra (R)) for the reversal of rivaroxaban-associated bleeding in an in vivo rabbit model, and evaluated the correlations between in vitro coagulation parameters and haemostasis in vivo. Results: Administration of single intravenous doses of rivaroxaban (150-450 mu g/kg) resulted in increased and prolonged bleeding following standardised kidney incision. Pre-incision treatment with 4F-PCC (25-100 IU/kg) resulted in a dose-dependent reversal of rivaroxaban (150 and 300 mu g/kg)-associated increases in time to haemostasis and blood loss; no reversal was seen at the highest rivaroxaban dose (450 mu g/kg). Of the in vitro biomarkers tested, thrombin generation and whole-blood clotting time correlated well with in vivo measures of 4F-PCC-mediated effects. Thrombin generation was highly reagent-dependent, with the assay initiated using the phospholipid-only reagent being the most predictive of effective haemostasis in vivo. Conclusions: In summary, in a rabbitmodel of acute bleeding, treatment with 4F-PCC reduced bleeding to control levels following rivaroxaban 150 mu g/kg and 300 mu g/kg administration. (C) 2015 The Authors. Published by Elsevier Ltd.
    Thrombosis Research 01/2015; 1(3). DOI:10.1016/j.thromres.2015.01.007 · 2.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Edoxaban is an oral, once-daily direct factor Xa (FXa) inhibitor that has been evaluated for stroke prevention in atrial fibrillation and for the treatment and secondary prevention of recurrent venous thromboembolism. Although rapidly cleared, strategies to reverse edoxaban-mediated effects on anticoagulation are needed in cases of excessive bleeding or emergency. This study evaluated the effect of two prohemostatic agents, recombinant factor VIIa (rFVIIa) and factor VIII inhibitor bypass activity (FEIBA), on the anticoagulatory effects of supratherapeutic concentrations of edoxaban in human whole blood ex vivo. Materials and Methods Blood samples were collected from six healthy volunteers. Edoxaban (500 or 1000 ng/mL), alone or followed by rFVIIa (0.8 or 1.8 μg/mL) or FEIBA (0.75 or 1.5 U/mL), was added to an aliquot of each sample. Biomarkers including prothrombin time (PT), activated partial thromboplastin time (aPTT), extrinsic FXa activity (anti-FXa), intrinsic factor X (FX) activity, and D-dimer were assessed at 0.25, 0.5, 1, 2, and 4 hours after adding rFVIIa or FEIBA. Results Decreases in measures of PT (p < 0.0001), aPTT (p < 0.0001), and anti-FXa (p < 0.0001) were observed when rFVIIa or FEIBA was added to edoxaban-containing blood samples. Intrinsic FX activity was increased up to 20% and 31% of normal in the presence of edoxaban by rFVIIa and FEIBA, respectively. The impact of these agents on the anticoagulant effects of edoxaban were observed within 15 minutes and remained relatively unchanged at each time point thereafter. Conclusions The findings of this ex vivo study suggest that rFVIIa and FEIBA rapidly reversed edoxaban-mediated anticoagulation effects.
    Thrombosis Research 10/2014; 134(4). DOI:10.1016/j.thromres.2014.07.036 · 2.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Treatment with new oral anticoagulant drugs does not require laboratory monitoring. However, there are some clinical settings where the measurement of the anticoagulant activity can be useful, especially in urgent surgery or invasive procedure. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) are prolonged with good correlation with plasma drug concentration. The influence of rivaroxaban on PT is greater than that on aPTT, in contrast to dabigatran. Apixaban responses to PT and aPTT are weak. These tests are not specific and cannot detect low plasma concentrations. For direct Factor-Xa inhibitors, the most appropriate test is a modified anti-Xa chromogenic assay. A specific test unresponsive to heparins and fondaparinux has been developed. For dabigatran measurement, a modified thrombin clotting time, “Hemoclot,” has been well documented. The use of plasma calibrators allows an expression of the results in ng/ml of plasma. Expected peak concentration (2 to 4 h after drug intake) and trough concentration or Cmin—before a repeated administration—have been determined. More clinical work is warranted to determine possible adjustments of the drug according to its plasma concentration. Finally, the potential advantage of a punctual screening during long-term treatment has not been investigated.
    Drug Development Research 12/2013; 74(8). DOI:10.1002/ddr.21118 · 0.73 Impact Factor